Journament

Keyword Connections - metastatic breast cancer Keywords

Connection Type	Connection
Journals	International journal of molecular sciences clinical & translational oncology : official publication of the federation of spanish oncology societies and of the national cancer institute of mexico Human molecular genetics Journal of the College of Physicians and Surgeons--Pakistan : JCPSP Cancer investigation psycho-oncology journal of palliative medicine the breast journal preventing chronic disease Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Research Groups	No Research Group Connected
Bibliographies	[1] Outcome and feasibility of palliative chemotherapy in very elderly patients with metastatic breast cancer. [2] Promoting Cancer Screening in Partnership With Health Ministries in 9 African American Churches in South Los Angeles: An Implementation Pilot Study. [3] Greater Mindfulness Associated With Lower Pain, Fatigue, and Psychological Distress in Women with Metastatic Breast Cancer. [4] A Trans-ancestral Meta-Analysis of Genome-Wide Association Studies Reveals Loci Associated with Childhood Obesity. [5] Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model. [6] "I'd Want to Know, Because a Year's Not a Long Time to Prepare for a Death": Role of Prognostic Information in Shared Decision Making among Women with Metastatic Breast Cancer. [7] Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. [8] the fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments [9] Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. [10] Prognostic Markers after Hepatic Function Impairment in Patients with Pancreatic Adenocarcinoma. [11] Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer. [12] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. [13] Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan. [14] Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer. [15] Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment [16] Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database. [17] The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2- metastatic breast cancer: Biological mechanisms and new treatments [18] Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. [19] Outcome and feasibility of palliative chemotherapy in very elderly patients with metastatic breast cancer. [20] Greater Mindfulness Associated With Lower Pain, Fatigue, and Psychological Distress in Women with Metastatic Breast Cancer. [21] Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer. [22] Reply to “Letter to the Editor” intent of surgery of the primary tumor in metastatic breast cancer remains palliative [23] Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer [24] Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model. [25] "I'd Want to Know, Because a Year's Not a Long Time to Prepare for a Death": Role of Prognostic Information in Shared Decision Making among Women with Metastatic Breast Cancer. [26] PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy [27] Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. [28] Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. [29] "The day you lose your hope is the day you start to die": Quality of life measured by young women with metastatic breast cancer. [30] High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. [31] Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: An Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. [32] Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index [33] Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study [34] effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer [35] nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities [36] changes in water mobility measured by diffusion mri predict response of metastatic breast cancer to chemotherapy [37] development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype [38] targeted treatment of advanced and metastatic breast cancer with lapatinib [39] safety and efficacy of tien-hsien liquid practical in patients with refractory metastatic breast cancer: a randomized, double-blind, placebo-controlled, parallel-group, phase iia trial [40] targeting metastatic breast cancer with ang1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (bbb) [41] time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the remagus02 study [42] Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after. [43] Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. [44] Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer. [45] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. [46] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast. [47] Ethanolic Extract of Hedyotis corymbosa L. Inhibits Migration and MMP-9 Activity on Metastatic Breast Cancer Cells [48] Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. [49] Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan. [50] The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer. [51] Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.